AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02242578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Description: About 1,000 stimulation pulses over 20 min
Study NCT02242578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Description: About 1,000 stimulation pulses over 20 min
Study NCT02662036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine HCL
Study NCT02662036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Study NCT00331045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan
Description: 0.25 mg/day
Study NCT00331045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00331045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg/day
Study NCT00331045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan 1 mg/day
Study NCT00974675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 1mg/kg
Description: CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
Study NCT00974675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 5 mg/kg
Description: CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
Study NCT00974675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 10mg/kg
Description: CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
Study NCT00974675 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
Study NCT01669070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 50 mcg
Description: Novel dry powder inhaler
Study NCT01669070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 100 mcg
Description: Novel dry powder inhaler
Study NCT01669070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 200 mcg
Description: Novel dry powder inhaler
Study NCT01669070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF, 250 mcg
Description: Intravenous
Study NCT02121262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
Study NCT02121262 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Photocoagulation
Description: Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
Study NCT00851201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle
Description: The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups.
Study NCT00851201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
Study NCT02992340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
Study NCT02992340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
Study NCT02992340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
Study NCT02820285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the staging of fibrosis liver
Description: The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
Study NCT02820285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determine the expression level of semaphorin
Description: The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
Study NCT02820285 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determination of the composition of immunity cells
Description: The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)
Study NCT00436800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m² over 10mg/m²/min
Study NCT00436800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m² over 2 hours.
Study NCT02988453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBT-CD
Description: MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
Study NCT03096730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is intravenously administrated before anesthesia induction
Study NCT03096730 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Normal saline is intravenously administrated before anesthesia induction
Study NCT03096730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated
Study NCT03096730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is intravenously administrated
Study NCT03096730 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil is intravenously administrated
Study NCT03096730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine is intravenously administrated before anesthesia induction
Study NCT03096730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalmefene
Description: Nalmefene is intravenously administrated before anesthesia induction
Study NCT03956914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placeob water 440 ml/day for 8 weeks
Study NCT03956914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep sea water
Description: Deep sea water 440 ml/day for 8 weeks
Study NCT04566770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV
Study NCT04566770 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
Description: Intramuscular other name:Ad5-nCoV
Study NCT03314974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSCT with TBI Regimen
Description: Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
Study NCT03314974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSCT with Non-TBI Regimen
Description: Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
Study NCT04279275 — intervention group
Intervention type: OTHER
Intervention: SURVEY
Description: QUESTIONAIRRE
Study NCT03379272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOLDSTANDARD
Description: RECORDING WITH EEG GOLDSTANDARD
Study NCT01464437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
Study NCT01464437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 100 mg BID
Study NCT01464437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 200 mg BID
Study NCT01464437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 100 mg QD
Study NCT01464437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 200 mg QD
Study NCT03379272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEURONAUTE
Description: RECORDING WITH NEURONAUTE
Study NCT00707928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerine
Description: nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Study NCT00707928 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Study NCT03880175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCC (Força à Comunidade e Crianças) program- direct beneficiary
Description: Households are directly linked to the FCC implementing organization
Study NCT03880175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCC (Força à Comunidade e Crianças) program- non-direct beneficiary
Description: Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
Study NCT03880175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti Stigma Information
Description: Adults in the households are provided anti-stigma information
Study NCT03880175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/AIDS Information
Description: The households receive information about HIV infection and AIDS
Study NCT03880175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ART Information
Description: The households receive information about antiretroviral therapy.
Study NCT03880175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/AIDS and ART Information Combined
Description: The households receive both information about HIV/AIDS and information about antiretroviral therapy.
Study NCT03880175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High coupon value
Description: The HIV testing coupons distributed to households in this group have higher values.
Study NCT00426257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary debulking
Description: Secondary debulking
Study NCT00426257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: secondary debulking with intraperitoneal chemotherapy
Description: secondary debulking with intraperitoneal chemotherapy
Study NCT01529437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual immunotherapy
Description: Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
Study NCT01529437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sublingual immunotherapy
Description: Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
Study NCT01529437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo sublingual immunotherapy
Description: SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
Study NCT01024010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01024010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01024010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT01024010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given IV
Study NCT03837639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm ergometer
Description: Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
Study NCT03837639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill ergometer
Description: Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
Study NCT03837639 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
Study NCT01464437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 151
Description: Drug: AMG 151 400 mg QD
Study NCT03232697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full version of the Montreal Cognitive Assessment
Description: Patients or subjects will be submitted to the full version of the MOCA
Study NCT03232697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 5 minutes version of the Montreal Cognitive Assessment
Description: The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
Study NCT02001259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural triamsinolone
Description: add drugs into catheter at 48 hr after surgery
Study NCT02001259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural lidocaine
Description: add into catheter at 48 hr after surgery
Study NCT04044300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single screw fixation
Description: A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
Study NCT04044300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative
Description: Continued pain management and physical therapy.
Study NCT02173860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided surgical revascularization
Study NCT02173860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided surgical revascularization
Study NCT01427985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine, Fentanyl, Mivacurium
Description: 1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg
Study NCT01427985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine, Fentanyl, Mivacurium
Description: 1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg
Study NCT00625469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5mg orally bid for first month, followed by 125mg bid thereafter
Study NCT02718755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle.
Study NCT02718755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle.
Study NCT02718755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle.
Study NCT01628471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine in combination with genistein
Description: decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
Study NCT03015571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagus inspection in Narrow Band imaging.
Description: During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
Study NCT03015571 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard High definition endoscopy.
Description: Whole procedure will be performed in standard High definition endoscopy.
Study NCT03015571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagus inspection in Narrow Band imaging and increased care.
Description: During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
Study NCT03015571 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard High definition endoscopy and increased care.
Description: Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
Study NCT01166737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Debulking Surgery (surgery in recurrent ovarian disease)
Description: Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
Study NCT00864643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00864643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT04046432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vigiis 101-LAB
Description: examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
Study NCT04046432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin was used as a placebo.
Study NCT02149940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heart-failure related pharmaceutical intervention
Study NCT02255409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
Description: 1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
Study NCT02255409 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
Description: 1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months